Healthcare Industry News: Boston Scientific
News Release - April 14, 2010
OrbusNeich Granted Patent for 'Stent with Helical Elements' - Patent Infringement Case Against Boston Scientific ExpandedHONG KONG and FT. LAUDERDALE, Fla., April 14 -- (Healthcare Sales & Marketing Network) -- OrbusNeich Medical, Inc. (the "Company"), a designer, developer, manufacturer and marketer of innovative medical devices for the treatment of cardiovascular diseases, today announced that on March 23, 2010, the Company was granted U.S. Patent No. 7,682,384 B2, entitled "Stent with Helical Elements." The patent relates to an expandable stent comprised of a plurality of helical segments. The Company noted that it has identified unlicensed use by Boston Scientific Corporation (NYSE:BSX ) of certain technologies protected under U.S. Patent No. 7,682,384 B2.
As the owner by assignment of all right, title, and interest in the "Stent with Helical Elements", OrbusNeich believes that its previously announced infringement claims against Boston Scientific in the United States District Court for the District of Massachusetts ("the Court"), specifically related to the Boston Scientific Liberte and TAXUS Liberte branded stents, could be expanded to include the newly granted patent. Accordingly, the Company today filed with the Court a motion to amend its existing complaint against Boston Scientific.
"OrbusNeich is pleased to have been awarded this valuable patent, which further recognizes the innovativeness of the Company in stent design," said Al Novak, President and Chief Executive Officer of OrbusNeich. "We are committed to taking all appropriate actions to ensure that our proprietary technology and extensive research and development efforts are to the benefit of OrbusNeich's investors, employees and physician customers and their patients – not those of competitors."
OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of cardiovascular diseases. Current products are the world's first pro-healing stent, the Genous Bio-engineered R stent™, as well as stents, balloons and guiding catheters marketed under the names of R stent™, Scoreflex™, SafeCut™, Sapphire™, Sapphire NC Avita™, Avita HP and Lumina™.
OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla., USA; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich, which has provided medical devices to physicians through its predecessor companies since 1979, supplies products today to interventional cardiologists in more than 60 countries. For more information, visit OrbusNeich.com.
Source: OrbusNeich Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.